{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:47:09Z","timestamp":1784832429671,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:00:00Z","timestamp":1506729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:00:00Z","timestamp":1506729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fodazione Arpa","award":["Progetto Luca Gambicorti"],"award-info":[{"award-number":["Progetto Luca Gambicorti"]}]},{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","award":["Fondi di Ateneo"],"award-info":[{"award-number":["Fondi di Ateneo"]}],"id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10637-017-0516-2","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T08:06:45Z","timestamp":1506758805000},"page":"340-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy"],"prefix":"10.1007","volume":"36","author":[{"given":"Francesco","family":"Pasqualetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gonnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cantarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durim","family":"Delishaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Ortenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Montrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ursino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Di Desidero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Mazzanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Zavaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giuseppe","family":"Naccarato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Paiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,30]]},"reference":[{"issue":"9","key":"516_CR1","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","volume":"15","author":"M Weller","year":"2014","unstructured":"Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W, European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395\u2013e403","journal-title":"Lancet Oncol"},{"issue":"10","key":"516_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"3","key":"516_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11060-013-1317-x","volume":"116","author":"R Soffietti","year":"2014","unstructured":"Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rud\u00e0 R (2014) Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neuro-Oncol 116(3):533\u2013541","journal-title":"J Neuro-Oncol"},{"issue":"17","key":"516_CR4","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","volume":"310","author":"A Omuro","year":"2013","unstructured":"Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310(17):1842\u20131850","journal-title":"JAMA"},{"issue":"4","key":"516_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","volume":"28","author":"OL Chinot","year":"2011","unstructured":"Chinot OL, de La Motte RT, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28(4):334\u2013340","journal-title":"Adv Ther"},{"issue":"1","key":"516_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11060-014-1365-x","volume":"117","author":"G Eisele","year":"2014","unstructured":"Eisele G, Wick A, Eisele AC, Cl\u00e9ment PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M (2014) Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neuro-Oncol 117(1):141\u2013145","journal-title":"J Neuro-Oncol"},{"key":"516_CR7","doi-asserted-by":"crossref","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M, European Organisation for Research and Treatment of Cancer (EORTC), Canadian Brain Tumor Consortium, CENTRIC study team (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10): 1100\u20131108","DOI":"10.1016\/S1470-2045(14)70379-1"},{"key":"516_CR8","doi-asserted-by":"crossref","unstructured":"Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group (2016). Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol 13(10): 627\u2013642","DOI":"10.1038\/nrclinonc.2016.79"},{"issue":"6","key":"516_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1568-7864(03)00062-4","volume":"2","author":"J Thacker","year":"2003","unstructured":"Thacker J, Zdzienicka MZ (2003) The mammalian XRCC genes: their roles in DNA repair and genetic stability. DNA Repair (Amst) 2(6):655\u2013672","journal-title":"DNA Repair (Amst)"},{"issue":"8\u20139","key":"516_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.dnarep.2004.04.012","volume":"3","author":"J Thacker","year":"2004","unstructured":"Thacker J, Zdzienicka MZ (2004) The XRCC genes: expanding roles in DNA double-strand break repair. DNA Repair (Amst) 3(8\u20139):1081\u20131090","journal-title":"DNA Repair (Amst)"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.oraloncology.2016.08.005","volume":"61","author":"K Shridhar","year":"2016","unstructured":"Shridhar K, Aggarwal A, Walia GK, Gulati S, Geetha AV, Prabhakaran D, Dhillon PK, Rajaraman P (2016) Single nucleotide polymorphisms as markers of genetic susceptibility for oral potentially malignant disorders risk: Review of evidence to date. Oral Oncol 61:146\u2013151","journal-title":"Oral Oncol"},{"issue":"9","key":"516_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/09553000210141441","volume":"78","author":"JF Sun","year":"2002","unstructured":"Sun JF, Sui JL, Zhou PK, Geng Y, Hu YC, Cao ZS, Ge SL, Lou TZ, Wu DC (2002) Decreased efficiency of gamma-ray-induced DNA double-strand break rejoining in malignant transformants of human bronchial epithelial cells generated by alpha-particle exposure. Int J Radiat Biol 78(9):773\u2013780","journal-title":"Int J Radiat Biol"},{"issue":"12","key":"516_CR13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1097\/01.mlg.0000183736.96004.f7","volume":"115","author":"TJ Gal","year":"2005","unstructured":"Gal TJ, Huang WY, Chen C, Hayes RB, Schwartz SM (2005) DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope 115(12):2221\u20132231","journal-title":"Laryngoscope"},{"issue":"7","key":"516_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101256","volume":"9","author":"H Jin","year":"2014","unstructured":"Jin H, Xie X, Wang H, Hu J, Liu F, Liu Z, Zhou J, Zhang Y, Xi X, Hu B, Liao Y, Tang J (2014) ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma. PLoS One 9(7):e101256","journal-title":"PLoS One"},{"issue":"1","key":"516_CR15","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1111\/ajco.12117","volume":"12","author":"XM Zhai","year":"2016","unstructured":"Zhai XM, Hu QC, Gu K, Wang JP, Zhang JN, Wu YW (2016) Significance of XRCC1 Codon399 polymorphisms in Chinese patients with locally advanced nasopharyngeal carcinoma treated with radiation therapy. Asia Pac J Clin Oncol 12(1):e125\u2013e132","journal-title":"Asia Pac J Clin Oncol"},{"issue":"16","key":"516_CR16","first-page":"4313","volume":"54","author":"KD Tew","year":"1994","unstructured":"Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54(16):4313\u20134320","journal-title":"Cancer Res"},{"issue":"2","key":"516_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.freeradbiomed.2011.04.013","volume":"51","author":"KD Tew","year":"2011","unstructured":"Tew KD, Manevich Y, Grek C, Xiong Y, Uys J, Townsend DM (2011) The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med 51(2):299\u2013313","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"516_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0969-2126(97)00281-5","volume":"5","author":"L Prade","year":"1997","unstructured":"Prade L, Huber R, Manoharan TH, Fahl WE, Reuter W (1997) Structures of class pi glutathione S-transferase from human placenta in complex with substrate, transition-state analogue and inhibitor. Structure 5(10):1287\u20131295","journal-title":"Structure"},{"issue":"2","key":"516_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1006\/bbrc.1997.7311","volume":"238","author":"X Hu","year":"1997","unstructured":"Hu X, Xia H, Srivastava SK, Herzog C, Awasthi YC, Ji X, Zimniak P, Singh SV (1997) Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 238(2):397\u2013402","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"516_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00008571-200210000-00006","volume":"12","author":"TM Ishimoto","year":"2002","unstructured":"Ishimoto TM, Ali-Osman F (2002) Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12(7):543\u2013553","journal-title":"Pharmacogenetics"},{"issue":"5","key":"516_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453\u2013461","journal-title":"Lancet Oncol"},{"issue":"2","key":"516_CR22","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s12035-016-9725-5","volume":"54","author":"L Qi","year":"2017","unstructured":"Qi L, Yu HQ, Zhang Y, Ding LJ, Zhao DH, Lv P, Wang WY, Xu Y (2017) A Comprehensive Meta-analysis of Genetic Associations Between Key Polymorphic Loci in DNA Repair Genes and Glioma Risk. Mol Neurobiol 54(2):1314\u20131325","journal-title":"Mol Neurobiol"},{"issue":"12","key":"516_CR23","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/neuonc\/nov064","volume":"17","author":"RW Rapkins","year":"2015","unstructured":"Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL (2015) The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro-Oncology 17(12):1589\u20131598","journal-title":"Neuro-Oncology"},{"issue":"2","key":"516_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-015-1974-z","volume":"126","author":"S Franceschi","year":"2016","unstructured":"Franceschi S, Tomei S, Mazzanti CM, Lessi F, Aretini P, La Ferla M, De Gregorio V, Pasqualetti F, Zavaglia K, Bevilacqua G, Naccarato AG (2016) Association between RAD 51 rs1801320 and susceptibility to glioblastoma. J Neuro-Oncol 126(2):265\u2013270","journal-title":"J Neuro-Oncol"},{"key":"516_CR25","doi-asserted-by":"publisher","unstructured":"Pasqualetti F, Orlandi P, Simeon V, Cantarella M, Giuliani D, Di Desidero T, Gonnelli A, Delishaj D, Lombardi G, Sechi A, Sanson M, Zagonel V, Paiar F, Danesi R, Guarini S, Bocci G (2017) Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-017-0414-9","DOI":"10.1007\/s12035-017-0414-9"},{"issue":"2","key":"516_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2014.07.023","volume":"353","author":"I Sullivan","year":"2014","unstructured":"Sullivan I, Salazar J, Majem M, Pallar\u00e9s C, Del R\u00edo E, P\u00e1ez D, Baiget M, Barnadas A (2014) Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 353(2):160\u2013166","journal-title":"Cancer Lett"},{"key":"516_CR27","doi-asserted-by":"crossref","unstructured":"Leguisamo NM, Gloria HC, Kalil AN, Martins TV, Azambuja DB, Meira LB, Saffi J (2017). Base excision repair imbalance in colorectal cancer has prognostic value and modulates response to chemotherapy. Oncotarget 8(33):54199-54214","DOI":"10.18632\/oncotarget.14909"},{"issue":"8","key":"516_CR28","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s00405-015-3740-4","volume":"273","author":"C Mu\u00f1oz","year":"2016","unstructured":"Mu\u00f1oz C, Caballero M, Hakim S, Verger E, Grau JJ (2016) Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab. Eur Arch Otorhinolaryngol 273(8):2193\u20132199","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"516_CR29","doi-asserted-by":"publisher","unstructured":"Liu HF, Liu JS, Deng JH, Wu RR (2016) Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics. Genet Mol Res 15(4). https:\/\/doi.org\/10.4238\/gmr15049084","DOI":"10.4238\/gmr15049084"},{"issue":"10","key":"516_CR30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997\u20131003","journal-title":"N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0516-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:14:28Z","timestamp":1678511668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0516-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,30]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0516-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,30]]},"assertion":[{"value":"18 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}